hta_ knee intro.qxp - Ministero della Salute

40
Table 7.5: Data from the Australian Orthopaedic Association National Joint Replacement Register
(AOAJRR) showing revision rates at 3 and 5 years by variables of the receiving population. This
table refers to cemented fixation only.
Knee system (cemented)
Total
obs.
Female/Male
[%]
Mean age
(range)
OA [%]
3 years
(95% CI)
5 year
(95% CI)
GENESIS II (SMITH & NEPHEW) 9,827 60/40 72 (-) 96.3 2.7 (2.4; 3.2) 3.5 (3.0; 4.0)
P.F.C. SIGMA (DEPUY) 8,984 60/40 70 (-) 96.2 2.0 (1.6; 2.3) 2.8 (2.3; 3.4)
DURACON (STRYKER) 8,183 61/39 71 (-) 95.9 2.4 (2.1; 2.8) 3.2 (2.8; 3.7)
NEXGEN CR (ZIMMER) 7,152 66/34 70 (-) 96.1 1.3 (1.0; 1.7) 1.7 (1.3; 2.2)
NEXGEN LPS FLEX (ZIMMER) 6,608 51/49 69 (-) 97.1 2.6 (2.2; 3.2) 3.3 (2.6; 4.2)
GENESIS II OXINIUM (SMITH & NEPHEW) 6,280 54/46 65 (-) 97.7 3.0 (2.5; 3.6) 5.1 (4.0; 6.4)
SCORPIO (STRYKER) 5,146 63/37 71 (-) 95.2 2.8 (2.3; 3.4) 3.7 (3.0; 4.4)
LCS (DEPUY) 4,110 60/40 70 (-) 95.1 3.7 (3.1; 4.3) 4.9 (4.2; 5.6)
NEXGEN LPS (ZIMMER) 3,808 57/43 70 (-) 96.6 2.1 (1.7; 2.7) 2.8 (2.3; 3.5)
PROFIX (SMITH & NEPHEW) 3,512 58/42 69 (-) 96.5 3.4 (2.7; 4.1) 4.0 (3.3; 4.8)
AGC (BIOMET) 2,679 58/42 70 (-) 97.1 2.2 (1.7; 2.9) 3.0 (2.3; 3.9)
TRIATHLON (STRYKER) 2,269 63/37 69 (-) 96.6 - (-; -) - (-; -)
KINEMAX PLUS (STRYKER) 1,681 56/44 70 (-) 97.7 2.3 (1.7; 3.2) 2.9 (2.1; 3.9)
NATURAL KNEE (ZIMMER) 1,167 71/29 73 (-) 94.4 1.5 (0.9; 2.5) 1.9 (1.1; 3.0)
OPTETRAK-PS (EXACTECH) 996 55/45 69 (-) 97.2 5.7 (4.2; 7.9) 6.9 (4.9; 9.5)
RBK SYSTEM (G.M.T.) 621 68/32 70 (-) 96.6 3.0 (1.6; 5.6) 3.0 (1.6; 5.6)
MAXIM (BIOMET) 552 68/32 70 (-) 95.8 2.8 (1.7; 4.8) 4.5 (2.8; 7.1)
ADVANCE (WRIGHT) 531 55/45 70 (-) 97.0 5.9 (4.1; 8.4) 6.5 (4.5; 9.2)
JOURNEY (SMITH & NEPHEW) 460 58/43 67 (-) 97.0 - (-; -) - (-; -)
ZIMMER MBK (ZIMMER) 296 63/37 68 (-) 95.3 2.7 (1.4; 5.4) 4.9 (2.9; 8.1)
BALANSYS (MATHYS) 230 50/50 71 (-) 95.2 2.8 (1.2; 6.7) 3.7 (1.7; 8.3)
ACTIVE KNEE (ASDM) 207 72/28 74 (-) 93.7 4.0 (1.9; 8.4) - (-; -)
I/B II (ZIMMER) 199 46/54 71 (-) 99.0 3.0 (1.4; 6.7) 6.8 (4.0; 11.4)
APOLLO (ZIMMER) 168 69/31 71 (-) 95.8 0.6 (0.1; 4.2) 0.6 (0.1; 4.2)
NEXGEN LCCK (ZIMMER) 122 69/31 70 (-) 83.6 - (-; -) - (-; -)
ADVANTIM (WRIGHT) 118 60/40 73 (-) 95.8 0.8 (0.1; 5.9) 0.8 (0.1; 5.9)
ROCC (BIOMET) 117 59/41 70 (-) 96.6 - (-; -) - (-; -)
GENESIS (SMITH & NEPHEW) 112 64/36 72 (-) 99.1 5.7 (2.6; 12.2) 6.7 (3.3; 13.6)
VKS (SMITH & NEPHEW) 110 52/48 71 (-) 98.2 - (-; -) - (-; -)
ROTAGLIDE+ (CORIN) 97 45/55 72 (-) 95.9 2.1 (0.5; 8.2) - (-; -)
OPTETRAK-CR (EXACTECH) 85 60/40 70 (-) 95.3 6.8 (2.9; 15.7) - (-; -)
OXFORD TMK (BIOMET) 75 55/45 62 (-) 94.7 1.3 (0.2; 9.1) 1.3 (0.2; 9.1)
SERIES 7000 (STRYKER) 67 40/60 76 (-) 98.5 1.5 (0.2; 10.3) 1.5 (0.2; 10.3)
AMK (DEPUY) 58 72/28 70 (-) 93.1 7.0 (2.7; 17.6) 12.3 (6.1; 24.1)
S-ROM (DEPUY) 56 55/45 68 (-) 60.7 - (-; -) - (-; -)
Key: obs. = observations; CI = confidence interval; - = not reported; G.M.T. = Global Manufacturing
Technology; ASDM = Advanced Surgical Design & Manufacture; OA = osteoarthritis.
Note: Missing revision rates were marked with “- (-; -)”. This means that estimates at follow-up can not be calculated
yet (e.g. the number of observations was too low for survival analysis or the follow-up did not reach
3 years).